SGLT-2i, a suitable therapeutic option for T2DM patients with multiple risk factors and comorbidities

Dr Shalini C Sree Dharan, a consultant endocrinologist, discusses the benefits of treatment options for type 2 diabetes mellitus (T2DM) that also address a patient’s underlying cardiovascular and hepatic dysregulation. Here, Dr Shalini discusses a case study where a fixed dose combination of a sodium/glucose cotransporter-2 inhibitor (SGLT-2i) and dipeptidyl peptidase-4 enzyme inhibitor (DPP-4i) provided benefits for both glucose control and cardiovascular risk reduction.